NEW YORK (GenomeWeb News) – Biomarker technology developer ApoCell has received an investment from Boston-based equity investor Summit Partners, which supports life sciences companies.

The amount of the investment was not disclosed.

ApoCell, which spun out from the University of Texas MD Anderson Cancer Center in 2005 and operates out of Houston, will use the funds to continue developing its technology platforms aimed at using biomarker signatures in oncology, diabetes, molecular diagnostics, and drug development.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

In Science this week: environmental DNA can help in studies of marine animals, and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
20
Sponsored by
PerkinElmer

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.

Jul
10
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.